ReviewNeurology2009
Invited article: human natural autoantibodies in the treatment of neurologic disease.
Review in Neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Natural autoantibodies and their functional therapeutic roles in intravenous immunoglobulin.Frontiers in aging · 2025Review
- Identification of the Lipid Antigens Recognized by rHIgM22, a Remyelination-Promoting Antibody.Neurochemical research · 2023Article
- The Forgotten Brother: The Innate-like B1 Cell in Multiple Sclerosis.Biomedicines · 2022Review
- Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases.Frontiers in pharmacology · 2019Review
- Multiple Sclerosis: Mechanisms of Disease and Strategies for Myelin and Axonal Repair.Neurologic clinics · 2018Review
- Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease.Molecular neurobiology · 2016Review
- A monoclonal natural human IgM protects axons in the absence of remyelination.Journal of neuroinflammation · 2016Article
- The Role of 3-O-Sulfogalactosylceramide, Sulfatide, in the Lateral Organization of Myelin Membrane.Neurochemical research · 2016Review
- A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis.Disease models & mechanisms · 2015Article
- A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis.Journal of neuroinflammation · 2015Article
- Myelin recovery in multiple sclerosis: the challenge of remyelination.Brain sciences · 2013Article
- Therapeutics to promote CNS repair: a natural human neuron-binding IgM regulates membrane-raft dynamics and improves motility in a mouse model of multiple sclerosis.Journal of clinical immunology · 2013Article
- Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy.Clinical reviews in allergy & immunology · 2012Review
- A human IgM signals axon outgrowth: coupling lipid raft to microtubules.Journal of neurochemistry · 2011Article
- Enhancing CNS repair in neurological disease: challenges arising from neurodegeneration and rewiring of the network.CNS drugs · 2011Review
- Role of γδ T cells in antibody production and recovery from SFV demyelinating disease.Journal of neuroimmunology · 2011Article
- Method of identifying natural antibodies for remyelination.Journal of clinical immunology · 2010Article
- Inflammation in neurodegenerative diseases.Immunology · 2010Review
- Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins.Biotechnology journal · 2009Review
- Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler's virus.Progress in neurobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Naturally occurring autoantibodies are molecules that are part of the normal immunoglobulin repertoire. This review focuses on three distinct groups of human monoclonal antibodies (mAb). These are human natural autoantibodies that, when injected into an animal model of human disease, stimulate remyelination in CNS demyelinating diseases, protect neurons and extend neuronal processes in CNS axonal disorders, and activate immune dendritic cells to produce cytotoxic T cells to clear metastatic tumors. Natural autoantibodies react to self antigens and are of relatively low affinity. They are derived from germline immunoglobulin genes and are usually polyreactive. Our experiments demonstrated CNS entry by autoradiography of labeled mAb and by MRI. Remyelinating mAb rHIgM22 clusters beta-integrin and mouse mAb O4 recognizes sulfatide. Neuronal outgrowth mAbs sHIgM42 and sHIgM12 appear to target carbohydrates on the surface of neurons. The mAb sHIgM12 (B7-DC-Xab) also is promising as therapeutic against metastatic tumors. It functions by binding and cross-linking the antigen B7-DC on dendritic cells, inducing tumor-specific cytotoxic T cells. All these mAbs activate a transient increase in intracellular calcium, signal via NFkappab, and prevent apoptosis. The mAbs engage downstream signaling events that induce the primary function of the cell (that is, remyelination for oligodendrocytes, axonal preservation and neurite extension for neurons, or antigen presentation for dendritic cells). Natural human auto mAbs are a potentially important therapeutic technique in combating a wide spectrum of disease processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.